Virginia Tech Researchers Join Cancer Prevention, Diagnosis and Treatment | VTx

May is a month to recognize the importance of cancer research, and both Brain Tumor Awareness Month and National Cancer Research Month play a central role. The Fralin Biomedical Research Institute at Virginia Tech’s VTC is dedicated to improving our understanding of cancer and developing new ways to treat and prevent it.

Research teams are working to elucidate the molecular mechanisms that drive cancer growth, migration, and metastasis. They work on cancers ranging from childhood cancer to breast cancer to glioblastoma, one of the deadliest brain tumors. Scientists are not only looking for new treatments, but they are also overcoming existing treatments by developing entirely new treatments that can make cancer cells more vulnerable, halt the course of the cancer and prevent it from recurring. We are working to make it more effective.

  • Prevents the spread of cell death after injury – Robert Gourdie’s lab is testing new compounds that target connexin channels for therapeutic use in wound healing, reducing scarring after breast reconstruction surgery, and treating glioblastoma and drug-resistant cancers .
  • Development of new cancer treatments – Samy Lamouille’s lab studies how cancer cells communicate. He targets these communication mechanisms to develop new therapeutic strategies to prevent metastasis in human cancer progression.
  • Connecting scientific disciplines to cure cancer – Carla Finkielstein studies the molecular clocks that tell cells when to grow, divide and die, and how they are compromised in cancer cells. Her research provides the basis for the emerging field of chronotherapeutics.
  • Understanding the Health Impact of Cancer Diagnosis – Warren Bickel studies how cancer diagnoses and an individual’s ability to think and plan for the future affect health.
  • Tracking Fluid Flow to Understand Cancer, Aging, and Women’s Health – Jenny Manson studies how cancer increases fluid flow between cells, altering how tumors respond to drug therapy. She is working to commercialize some of her own discoveries at her biotech startup Cairina Inc. Cairina Inc.’s technology enables clinicians to fight cancer and provide personalized care by mapping individual tumors.
  • Finding new treatments to fight childhood brain tumors – At the Fralin Biomedical Research Institute at the VTC Lab at the National Institute of Children’s Research in Washington, DC, Jia-Ray Yu calls for a better understanding and treatment surrounding pediatric midline gliomas, and Kathleen Mulvaney for better cancer treatments I study cell communication to find a way.

But we are not working alone. The Virginia Tech Cancer Research Alliance collaborates with cancer scientists at multiple universities and medical centers to introduce innovative preventive, diagnostic, and therapeutic approaches for a wide range of cancers. On May 25, the 2nd Annual Virginia Tech Alliance for Cancer Research Retreat will be held at the Children’s National Research and Innovation Campus in Washington, DC. There, alliance members share research, forge new collaborations, and learn from keynote speakers that span veterinary and human science. Oncology and biomedical cancer research.


To secure an interview with a cancer researcher, please contact Leigh Anne Kelley of the VTC’s Fralin Biomedical Research Institute. 703-399-9494.

About VTC’s Fralin Biomedical Research Institute

of VTC’s Fralin Biomedical Research Institute is one of the nation’s fastest growing academic biomedical research companies and a destination for world-class researchers. Virginia Tech scientists at the institute focus on diseases that are the leading causes of death and suffering in the United States, including brain disorders, heart disease and cancer. We have achieved tremendous growth. He doubled the corporate and laboratory facilities in Roanoke and invested in a new laboratory at the Children’s National Research & Innovation Campus in Washington, DC.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *